proximately 12% for a year following the diagnosis of NM 3, 4, 14, 15 using this treatment approach. Because NM is characterized by infiltration of cancer cells throughout the leptomeninges and subarachnoid space, obstruction of CSF flow is common 8, 13 and leads to elevated intracranial pressure and hydrocephalus in half of patients. 9, 22, 25 Without CSF diversion, patients with hydrocephalus or increased intracranial pressure can develop debilitating headaches, and cognitive, gait, sphincter, and other neurological deficits, sometimes including herniation and death. Cerebrospinal fluid diversion techniques such as ventriculoperitoneal and lumboperitoneal shunting are safe and effective in treating hydrocephalus from multiple etiologies, but these techniques have not been used extensively in patients with NM, in part due to therapeutic nihilism and in part due to concerns about peritoneal spread of cancer. 1, 21 Furthermore, administering intrathecal chemotherapy to patients with ventriculoperitoneal shunts is problematic because a functioning ventriculoperitoneal shunt will shunt chemotherapy out of the CSF space, making it difficult to maintain an effective concentration of chemotherapy within the CSF. To address these concerns, we have used a combined treatment approach for NM patients with hydrocephalus that employs an in-line CSF reservoir for injection of intraventricular chemotherapy, an on-off valve for CSF flow control, and a programmable ventriculoperitoneal shunt for diversion of CSF (RO-VPS). In this paper, we review our experience with this approach.
Methods

Patient Selection
Demographic and clinical outcome data from patients who underwent ventriculoperitoneal shunt placement were prospectively collected at the Brigham and Women's Hospital/Dana-Farber Cancer Institute and the Huntsman Cancer Institute, University of Utah with institutional-review-board -approved protocols. All patients treated with ventriculoperitoneal shunts were at least 18 years of age, carried the diagnosis of NM, and had symptomatic hydrocephalus. Most patients underwent lumbar puncture prior to shunt placement to demonstrate high opening pressure and/or volume-dependent neurological symptoms. Identical demographic and outcome data were collected from a contemporaneous group of patients with NM and no hydrocephalus treated at the Brigham and Women's Hospital/Dana-Farber Cancer Institute who underwent Ommaya reservoir placement without shunt placement. Patients were monitored carefully during the study period for signs and symptoms of elevated intracranial pressure, such as worsening headache, nausea, vomiting, blurry vision, mental status changes, or gait changes. If elevated intracranial pressure was confirmed via lumbar puncture and an Ommaya reservoir had already been placed, a ventriculoperitoneal shunt would be placed on the contralateral side. Informed consent was obtained from all patients for all surgical procedures.
Design of the RO-VPS Construct
The RO-VPS construct consists of a Codman Holter reservoir (Codman Inc.) connected in series with an onoff valve (Integra LifeSciences), a programmable shunt valve (Codman Hakim valve, in-line design), and distal peritoneal tubing (Fig. 1) . The connection between each component is achieved via straight connectors with silk ties. The construct measures approximately 11 cm in length, compared with 3 cm for the valve only. We chose to use both an on-off valve and a programmable valve, which could be dialed from 30 mm Hg to 200 mm Hg, because of concerns that frequent adjustment of the programmable valve setting could be associated with increased risk of shunt failure. It is also important to have the on-off valve in between the Ommaya reservoir and the shunt valve because switching it off prevents the shunt valve from being exposed to external pressure when the reservoir is used for injection. During the operative procedure, a ventricular catheter is placed intracranially, and is then attached to the Ommaya reservoir. All patients received an intravenous injection of antibiotic agent (Vancomycin 1 gm at Brigham and Women's Hospital, Ancef 1 gm at the Huntsman Cancer Institute) prior to incision. After the operation, a CT scan of the head and skull radiographs (shunt series) were obtained in all cases to confirm appropriate ventricular catheter placement and the appropriate shunt pressure setting (Fig. 1) . A CSF flow study (with the on-off valve closed or with the programmable valve turned up to the highest setting) was performed in all cases prior to the first administration of intraventricular chemotherapy to demonstrate appropriate CSF distribution of tracer and patency of CSF pathways. 5, 9, 13, 16 
Intrathecal Chemotherapy Protocol
As early as 48 hours after placement of an RO-VPS system, patients were treated with intraventricular chemotherapy selected by the treating neurooncology team. Prior to an intrathecal injection, the treating oncologist manually closed the on-off valve, effectively stopping the CSF flow toward the peritoneal space. The Ommaya reservoir was accessed via a 25-gauge needle, and the opening pressure was measured prior to chemotherapy administration to confirm a pressure less than 200 mm of water. The on-off valve stayed closed for 2-6 hours after the injection while the patient was closely monitored in the clinic. The valve was promptly switched open if the patient developed symptoms suggestive of increased intracranial pressure such as worsened headache, nausea, vomiting, or confusion. It was observed that over time most patients could tolerate longer duration of valve closure; as a result, in many patients the valve was kept closed for up to 24 hours. Intrathecal chemotherapy was mostly carried out in an outpatient setting and rarely was admission required after a treatment.
Data Analysis
Follow-up was performed twice weekly to once monthly depending on the patient's chemotherapy regimen and clinical course. All electronic and paper medical records were reviewed. Demographic characteristics and perioperative medical conditions were recorded, including age, sex, extent of systemic cancer, CSF chemistry, cell count, cytology, radiographic findings, concurrent che motherapy and radiation therapy, pre-and postoperative Karnosfky Performance Scale (KPS) scores, and progression-free and overall survival. Perioperative complications, length of hospital stay, and postoperative relief of symptoms were also extracted from the medical records. Disease progression was defined as either clinical deterioration attributed by the treating team to NM, positive results of CSF cytological analysis after initial clearing, or radiographic worsening of CNS disease. The KPS score, disease-related symptoms, and treatment-related side-effects were reported by the patient's treating neurooncology team in the medical record. Independentsample t-tests and log-rank tests were performed. All statistical analyses were performed with Excel (Microsoft Corp.) and SPSS 15.0 (SPSS, Inc.).
Results
Patient Cohorts
Between 2005 and 2009, 24 patients underwent surgical placement of RO-VPS constructs at our 2 institutions. Two patients were lost to follow-up. A comparison ("control") group consisted of 26 consecutive patients who were diagnosed with neoplastic meningitis, had Ommaya reservoirs placed, and received intrathecal chemotherapy at the Brigham and Women's Hospital/DanaFarber Cancer Institute during the same 4-year interval. Two patients in the control group who initially underwent placement of an Ommaya reservoir alone subsequently developed symptomatic hydrocephalus and underwent placement of a ventriculoperitoneal shunt on the contralateral side. Both of these patients received intrathecal chemotherapy following the second operation and were included in the RO-VPS group. Thus, data from 24 patients were available for analyses from each group. The 2 groups were nearly identical with respect to demographic characteristics, systemic cancer spread, functional status (measured by preoperative KPS score), and treatment, apart from the type of ventricular access or shunting device they received (Table 1) . A total of 29 patients were treated with whole brain radiation therapy prior to shunt or Ommaya reservoir placement, and 14 patients also received stereotactic radiosurgery for focal intracranial lesions. The distribution of patients treated with radiation therapy is similar between the 2 groups.
The median age of the patients at surgery was 57 years (range 23-75 years) in the RO-VPS group and 53.5 years (range 27-87 years) in the control group. Breast cancer was the most common primary cancer diagnosis in both groups. In the RO-VPS group, 7 patients had leptomeningeal spread of primary brain cancer (4 anaplastic astrocytomas, 2 glioblastomas, 1 medulloblastoma), as did 5 patients in the control group (2 anaplastic astrocytomas, 2 glioblastomas, 1 oligodendroglioma). At diagnosis of NM, the majority of patients (76.9%) complained of headache, although ataxia, nausea/vomiting, visual changes, and cranial nerve palsies were also frequently present. Approximately two-thirds of patients (66.7% in the RO-VPS group and 70.8% in control group) had systemic cancer spread or other brain parenchymal metastases prior to the diagnosis of NM. Most patients in both groups had had prior systemic chemotherapy or radiation therapy, and about one-third (45.8% in the RO-VPS group and 29.3% in the control group) had undergone a craniotomy for either resection or biopsy of intracranial metastases.
Cerebrospinal fluid was examined in all patients in both groups prior to surgery. Fourteen patients (53.8%) in the RO-VPS group had elevated intracranial pressure prior to shunt placement, documented either by lumbar puncture or during the surgical procedure itself, although not all opening pressures were quantitatively recorded. 
Safety of RO-VPS Placement
There was no perioperative mortality. Two postoperative complications were observed (8.3%). One patient had an obvious kink in the shunt tubing on the postoperative skull film and required immediate revision. The other patient suffered a fall postoperatively and developed a subdural hematoma, which required surgical evacuation. The shunt had to be revised in another patient 3 months after the original operation due to valve failure. There was no shunt infection during the follow-up period. The median length of hospital stay was 2.5 days after RO-VPS placement. Four patients were hospitalized for more than 10 days perioperatively because of medical complications unrelated to their surgery or treatments required for their cancer.
During this study, no routine abdominal imaging was performed unless indicated by new onset of symptoms or for staging purposes. No clinical symptoms were observed that suggested the development of peritoneal carcinomatosis or toxicity from intrathecal chemotherapy agents. In one patient with isolated leptomeningeal breast cancer, whole-body PET CTs were performed every 6 months after RO-VPS placement, and no new abdominal pathology was discovered during 17 months of follow-up.
Benefits of RO-VPS Surgery
Patients who were referred to the neurosurgery clinic with a diagnosis of NM and with symptoms of hydrocephalus usually underwent RO-VPS placement within 3 days. Patients exhibited steep functional decline (as measured by KPS score) from the time of the initial diagnosis of cancer to the time when they developed symptoms of NM. This downward trend was reversed after RO-VPS placement (Fig. 2) , and the beneficial effect was sustained over time. Most patients who received RO-VPS constructs had rapid relief of preoperative symptoms of headache, nausea, and gait disturbance (20 [83.3%] of 24). The mean KPS score at the first routine postoperative follow-up appointment (usually 1-2 weeks after the operation) was significantly higher than that at the preoperative evaluation (67.6 vs 53.6, p < 0.05). This improvement was sustained for the entire 6-month follow-up period of this series in 10 (41.7%) of 24 patients.
Survival After RO-VPS Surgery
Eighteen of the 24 patients in the RO-VPS group received intrathecal chemotherapy. Other concurrent postoperative treatment consisted of systemic chemotherapy in 21 patients (87.5%) and radiation therapy in 16 (66.7%). In 11 of the 18 patients who received intrathecal chemotherapy, the best cytological response to treatment was complete clearing of malignant cells on at least 2 separate, consecutive CSF samplings at least 1 week apart. In the control group, 20 patients (83.3%) received intrathecal chemotherapy, 13 (54.2%) underwent postoperative radiation, and 19 (79.2%) had systemic chemotherapy. The median follow-up period was 14 weeks. Twentythree patients (95.8%) showed disease progression during follow-up. The median overall survival was 19.5 weeks (95% CI 5.9-29.5 weeks, range 2.7-67.7 weeks) and progression-free survival 8.4 weeks (95% CI 1.0-13.9 weeks, range 1.8-54.6 weeks). When analyzing the length of overall survival according to primary cancer diagnosis, breast cancer patients in the RO-VPS group had significantly better survival than those in the control group (35 vs 21 weeks, p = 0.04), whereas there was no statistically significant difference in patients with other primary diagnoses ( Table 2 ). The overall survival in the RO-VPS group altogether was also better than that in the control group, using the Kaplan-Meier method (p = 0.008, Fig. 3 )
Intrathecal chemotherapy agents included Depocyt (cytarabine liposome injection), cytosine arabinoside, trastuzumab, and thiotepa. The choice of intrathecal chemotherapy agents was determined by the treating neurooncologist based on the patient's primary cancer history. No severe intrathecal chemotherapy-related side effects were observed and all patients received oral steroid therapy during intrathecal chemotherapy. Two patients developed new-onset seizures after intrathecal chemotherapy was started; they were found to have progression of disease on brain MR imaging.
Discussion
Neoplastic meningitis is a devastating complication of cancer and is increasing in frequency.
12 Elevated intracranial pressure and hydrocephalus are important contributors to clinical symptoms and poor prognosis and can be present in as many as half of all patients. 9, 22, 25, 26 These complications produce neurological deficits that significantly impair quality of life. Although ventriculoperitoneal shunting is a well-established, easily performed, and effective treatment for hydrocephalus, few patients with NM undergo this procedure. 22, 25 Reasons for withholding this intervention include: 1) therapeutic nihilism, 2) concerns about the morbidity of the procedure and the frequent failure of the shunt apparatus in this patient population, 3) concerns about producing peritoneal carcinomatosis, and 4) concerns that shunt placement will either render intraventricular chemotherapy ineffective or increase its toxicity by shunting the chemotherapy drugs directly into the peritoneal cavity.
The use of an on-off valve in conjunction with a ventriculoperitoneal shunt system to administer intrathecal chemotherapeutic agents or antibiotic therapy has been reported in the literature. 11, 20 With the advancement of programmable valves, the on-off valve has been less frequently used, as adjusting a programmable valve to the maximum setting prior to intrathecal injection has become a more common practice. 28 We chose to use an on-off valve because it was easily accessible to neurooncologists and because it reduced the need for frequent manipulation of the programmable shunt valve. In the current study, the placement of an RO-VPS construct was associated with a very low rate of morbidity (8.3%), no perioperative infection, and no perioperative death. This is especially notable because patients with NM are potentially high-risk candidates for ventriculoperitoneal shunt placement. Prior chemotherapy and radiation therapy can result in impaired wound healing; treatment-and diseaserelated immunosuppression can cause increased susceptibility to infection; and prior craniotomies and the presence of malignant cells and high protein in the CSF can result in a higher failure rate for the ventriculoperitoneal shunt in these patients than in patients who do not have cancer. Our experience compares favorably with similar published reports, in which significant complications occurred in about 10% of patients. 22, 25 In addition to being associated with a low complica- Fig. 2 . Karnofsky Performance Scale scores before and after shunt placement. The KPS score drops precipitously from the initial diagnosis of primary cancer to just prior to the RO-VPS placement procedure. This trend is reversed after the operation and the effect is sustained for up to 6 months. The time stamps indicate diagnosis of primary cancer (Initial Dx), diagnosis of NM (NM Dx), prior to surgical placement of RO-VPS construct (Pre-op), 2 weeks after the operation (Post-op), 3 months after the operation, and 6 months after the operation.
tion rate, the RO-VPS constructs were effective at relieving the symptoms of hydrocephalus (in 20 [83.3%] of 24 patients) and permitted intraventricular chemotherapy to be administered in all patients in whom this intervention was deemed appropriate. In those patients in whom intraventricular chemotherapy was delivered, we saw no unusual or clinically concerning toxicity, and we observed evidence of treatment efficacy, with cytological clearing of the CSF in 11 (61.1%) of 18 patients. The observed median survival of 31 weeks in this study also compares favorably with published studies reporting a median overall survival of 8-30 weeks. 4, 14, 15, 18 The survival advantage was especially notable in breast cancer patients who were treated with RO-VPS systems compared with those who had an Ommaya reservoir only (p = 0.04). This difference could most likely be explained by the effective CSF diversion provided by the ventriculoperitoneal shunt, given that patients in both groups received Depocyt intrathecal chemotherapy. Moreover, in a separate analysis within the RO-VPS group, we compared the length of overall survival in those who received intrathecal chemotherapy and those who did not. The patients who underwent both RO-VPS placement and intrathecal chemotherapy had longer median overall survival (data not shown), although the difference was not statistically significant. These results suggest that both CSF diversion and intrathecal chemotherapy are important treatment modalities for NM patients with hydrocephalus, a subgroup of patients usually associated with poor outcomes. 6, 17, 19 There are several limitations to be considered in interpreting these results. The study was a retrospective case-control study, treatment assignment was not randomized, and sample sizes were small. Meanwhile, important differences between groups were present despite demographic similarities; for example, the RO-VPS and Ommaya reservoir (no-ventriculoperitoneal shunt) groups also differed with respect to the presence of hydrocephalus and increased intracranial pressure. Nevertheless, hydrocephalus and intracranial pressure elevation are usually considered to herald advanced leptomeningeal disease and thus portend a poor prognosis. Another observation that we could not analyze was the duration of closure of the on-off valve (which depended on patient tolerability) after injection of intrathecal medications, but we felt clinically that longer duration of closure was observed after repeated intrathecal chemotherapy trials, probably due to improved CSF circulation and reabsorption.
Conclusions
In many patients who suffer from NM, hydrocephalus and elevated intracranial pressure are responsible for rapidly declining neurological status and eventual poor outcome. Our experience suggests that CSF diversion surgery in conjunction with intrathecal chemotherapy may provide important benefits to an appreciable proportion of patients with NM. Prospective clinical studies are needed to validate this approach in patients with NM.
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